Avalo Therapeutics Inc
$ 14.19
7.91%
06 Feb - close price
- Market Cap 262,696,000 USD
- Current Price $ 14.19
- High / Low $ 14.45 / 13.19
- Stock P/E N/A
- Book Value 5.13
- EPS -13.42
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -1.75 %
- 52 Week High 20.72
- 52 Week Low 3.39
About
None
Analyst Target Price
$36.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-27 | 2024-11-07 | 2024-08-12 | 2024-05-13 | 2024-03-28 | 2023-11-09 | 2023-08-03 | 2023-05-04 | 2023-03-29 |
| Reported EPS | -2.19 | -1.92 | -1.2867 | -2.74 | -1.25 | -14.07 | -141 | -116.21 | -0.11 | -0.59 | -0.85 | -1.04 |
| Estimated EPS | -1.22 | -1.19 | -1.605 | 1.665 | -1.19 | -6.7 | -1.18 | -4.8 | -1.1 | -0.8 | -0.97 | -0.73 |
| Surprise | -0.97 | -0.73 | 0.3183 | -4.405 | -0.06 | -7.37 | -139.82 | -111.41 | 0.99 | 0.21 | 0.12 | -0.31 |
| Surprise Percentage | -79.5082% | -61.3445% | 19.8318% | -264.5646% | -5.042% | -110% | -11849.1525% | -2321.0417% | 90% | 26.25% | 12.3711% | -42.4658% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.54 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVTX
2026-02-05 00:59:08
Avalo Therapeutics (AVTX) saw its shares increase significantly after Guggenheim initiated coverage with a "Buy" rating and a price target of $2. The analyst noted Avalo's strong cash position and two pipeline assets with upcoming data readouts as key drivers for potential growth and investor interest.
2026-02-04 23:29:20
Avalo Therapeutics (AVTX) shares jumped following Guggenheim's initiation of coverage with a Buy rating. The firm set a price target of $20 for the biopharmaceutical company, which is focused on developing treatments for inflammatory diseases. This positive analyst coverage reflects confidence in Avalo's future prospects and pipeline.
2026-02-04 11:59:09
Avalo Therapeutics, a clinical stage biotechnology company, announced its participation in two upcoming investor conferences: the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. Management will hold fireside chats at both events. The company focuses on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead asset, AVTX-009, currently in a Phase 2 clinical trial for hidradenitis suppurativa.
2026-02-04 11:59:09
Avalo Therapeutics (Nasdaq: AVTX) announced that its management will participate in two investor conferences in February 2026. The company will hold a fireside chat at the Guggenheim Emerging Outlook Biotech Summit on February 11 and another at the Oppenheimer Healthcare Life Sciences Conference on February 25. Live webcasts and replays of both events will be available on Avalo's investor website.
2026-02-02 23:59:09
Avalo Therapeutics Inc. (NASDAQ: AVTX) experienced a 5.8% rise in premarket trading after Guggenheim initiated coverage with a Buy rating and a $50 price target. Analyst Yatin Suneja highlighted the potential of Avalo’s AVTX-009 for hidradenitis suppurativa, projecting significant market capitalization growth and peak global sales of $2.1 billion. The company is conducting a Phase II study with topline data expected in Q2 2026 and plans a pivotal study in 2027.
2026-02-02 23:29:20
Cantor analyst Prakhar Agarwal suggests Avalo Therapeutics (AVTX) stock could see a significant rally, potentially over 200% upside if its AVTX-009 drug shows 25-30% HiSCR75 change in its Phase 2 LOTUS trial for hidradenitis suppurativa, with topline data expected in mid-2026. Despite recent underperformance compared to the biotech ETF, several analysts have initiated or reiterated 'Buy' ratings with target prices ranging from $25.00 to $50.00, indicating a bullish outlook. The company's management is confident in AVTX009's superior affinity and stronger IL-1b inhibition compared to competitors.
